The company said that its global clinical operations (GCO) unit will establish this global set of standards, policies and practices, and build a management system that will oversee clinical trials worldwide.
This model is designed to enhance how the company plans and manages the progression of therapeutic compounds through clinical trials toward commercialization.
“When fully implemented, the new model we are adopting is designed to result in a global, standardized approach to how we conduct clinical trials,” said Brent Saunders, senior vice president of global compliance and business practices, and project executive chair. “This new model, which replaces a previously decentralized approach, should help ensure better planning and prioritization, greater consistency in trial execution and improved cost efficiencies.”